PHARMACEUTICAL HUB SWITZERLAND BASEL REGION
TABLE OF CONTENTS
Preface 4 Pharmaceutical Industry in Switzerland Swiss Pharmaceutical Cluster Basel Region Innovation Capacity Inward Investment Factors
6 8 10 18 26
Company Profiles 32 Glossary 38
BASEL REGION
3
PREFACE
Councillor Christoph Brutschin, Director of the Department of Economic, Social and Environmental Affairs, Canton of Basel-Stadt
In recent years, the pharmaceutical industry has become one of the most important pillars and driving forces for the regional economy in various Swiss cantons. This sector generates around one quarter of the nominal value added in the Basel Region. Basel is the Swiss pharmaceutical cluster par excellence. With 28,500 employees, almost two thirds of all Swiss pharmaceutical industry staff work in the Basel Region cluster. The bulk of Switzerland’s pharmaceutical value added is created in Basel and the surrounding area. Moreover, the industry ploughs back a large proportion of its turnover into local research and development (R&D). The strong focus on research is evident from patent applications amongst other things. The region is world class in this respect. The companies located here typically cover the entire value added chain – from research and development via production and marketing to global head office operations. Consequently, other upstream and downstream industries also benefit greatly. It is estimated that every job in the pharmaceutical industry generates another three full-time positions in companies in other industries.
4
PHARMACEUTICAL HUB SWITZERL AND
The region’s appeal for existing and new life sciences companies is based on attractive local framework conditions. In addition to the tax incentive, the high quality of training and research institutions as well as hospitals play a crucial role. The open labour market and excellent accessibility by rail, road, sea and air ensure the companies’ access to employees and goods markets. In order for Basel to maintain and further expand its leading position, industry and public sector are working together to shape the future through the life sciences strategy adopted by the cantons of Basel-Landschaft and Basel-Stadt in conjunction with the Basel Chamber of Commerce. “DayOne. swiss” creates the Swiss innovation hub for “Precision Medicine”, i.e. linking therapy, diagnostics and digital tools. Basel and the pharmaceutical industry want to continue to grow together in the future, motivating each other at the same time.
BASEL REGION
5
PHARMACEUTICAL INDUSTRY IN SWITZERLAND
7.2%
AVERAGE ANNUAL GROWTH RATE OF REAL GROSS VALUE ADDED (2006–2016)
4.3× MORE PRODUCTIVE THAN OVERALL ECONOMY (2016)
SWISS FRANCS NOMINAL GROSS VALUE ADDED (2016)
45,500 EMPLOYEES (2016)
Study on behalf of Interpharma Further information on the economic importance of the Swiss pharmaceutical industry is provided in our publication, entitled “The Importance of the Pharmaceutical Industry for Switzerland”. This is available on our website at Publikationen/Pharmastandort. 6
PHARMACEUTICAL HUB SWITZERL AND
Source: BAK Economics, Polynomics, FSO, 2017
28.9 BN.
The pharmaceutical industry significantly impacts the Swiss economy both directly and indirectly. The direct economic importance can be measured, for example, by the value of exports, number of employees or gross value added (GVA). The latter is calculated by deducting the value of intermediate goods and services from the goods produced (production value). In 2016, the nominal GVA of the pharmaceutical industry amounted to 28.9 billion Swiss francs – an approximate fourfold increase compared to 20 years earlier. With an average annual growth rate of real GVA of 7.2 per cent, the pharmaceutical industry has impacted considerably on the growth of the Swiss economy in recent years. The indirect effects of the pharmaceutical industry can be measured in addition to its direct effects. Approximately 138,000 additional (full-time) jobs have been generated through cross-industry collaboration with other companies, taking pharmaceutical industry intermediate goods and services into account. Similarly, the employee demand for consumer goods and services together with the tax revenue from the pharmaceutical companies have an indirect effect on the overall economy. The direct and indirect GVA amount to approximately 49.6 billion Swiss francs. Furthermore, pharmaceutical companies in Switzerland invest heavily in research and development (R&D). In 2012, the share of private-sector investment in R&D accounted for around 2 per cent of the national gross domestic product (GDP). This high rate of investment highlights the importance of the Swiss research hub. In addition, the sector is making a significant contribution to ensuring that Switzerland is also perceived as an innovation driver internationally, leading the European and global innovation rankings. BASEL REGION
7
Around
88%
OF THE SWISS PHARMACEUTICAL INDUSTRY NOMINAL GROSS VALUE ADDED was achieved in the Basel Region, Espace MittellandBassin Lémanique and Zurich-Zug-Lucerne clusters in 2016.
n Basel Region n Espace Mittelland-
Bassin Lémanique n Zurich-Zug-Lucerne
n Schaffhausen n Ticino n Valais
8
PHARMACEUTICAL HUB SWITZERL AND
Source: BAK Economics, 2018
SWISS PHARMACEUTICAL CLUSTER
Basel Region The Basel Region Pharmaceutical Cluster comprising the cantons of Basel-Stadt, Basel-Land and Jura together with Fricktal and Dorneck-Thierstein, is of major international importance. International companies such as Actelion, Bayer, Boehringer Ingelheim, Novartis and Roche are located in this area. Espace Mittelland-Bassin Lémanique The cantons of Bern, Fribourg, Neuchâtel and Solothurn are located in the Espace Mittelland Area whilst the Geneva and Vaud cantons are located in the Bassin Lémanique Area. Together they form the Espace Mittelland-Bassin Lémanique cluster, which is home to the Swiss branches of Biogen, Celgene, Eli Lilly, GlaxoSmithKline, Merck, Sanofi, UCB and Vifor Pharma. Zurich-Zug-Lucerne The Zurich-Zug-Lucerne cluster has grown into an attractive location for international life sciences companies. It is home to the following companies: AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Bristol-Myers Squibb, Gilead, Janssen, Lundbeck, Merck, MSD (Merck Sharp & Dohme), Novartis, Pfizer, Roche, Shire, Takeda and Vifor Pharma. Schaffhausen / Ticino / Valais There are also three smaller pharmaceutical clusters in Switzerland: In Schaffhausen, the pharmaceutical industry plays an important role for the local economy and is based primarily on the activities of Cilag. In the Ticino cluster, the pharmaceutical industry has grown historically and now includes several medium-sized companies. Valais is extremely important as the area accommodates suppliers who produce chemical inputs for pharmaceutical production. BASEL REGION
9
BASEL REGION THE PHARMACEUTICAL INDUSTRY IN THE BASEL REGION CLUSTER
7.3%
AVERAGE ACTUAL ANNUAL GROWTH RATE OF GROSS VALUE ADDED (2006–2016)
112
PATENT APPLICATIONS in 2013 (per million inhabitants)
20.5 BN. SWISS FRANCS NOMINAL GROSS VALUE ADDED
28,500 EMPLOYEES in 2016
10
PHARMACEUTICAL HUB SWITZERL AND
Source: OECD, BAK Economics, 2018
(2016)
The manufacture of medical devices is amalgamated with the life sciences industry. This includes the pharmaceutical industry, medical technology (electric and orthopaedic) as well as biotechnology, all of which are heavily engaged in research and development. The Basel Region is Switzerland’s leading life sciences location and has a long history of chemical-pharmaceutical industry tradition. Numerous life sciences companies are located in this region. These companies fully cover the entire value added chain of the pharmaceutical industry – from research and development to production and marketing. The largest share of Switzerland’s entire pharmaceutical value added is generated in the Basel Region cluster. The region also appeals to life sciences companies because of favourable framework conditions. The Basel Region cluster is characterised by the presence of prestigious educational and research institutions and employs the most life sciences specialists nationwide. Furthermore, its close proximity to Germany and France, to the international airport of Basel-Mulhouse-Freiburg and the Swiss Rhine ports provides excellent access to all major transport routes.
BASEL REGION
11
BASEL REGION
EMPLOYMENT IN THE LIFE SCIENCES SECTOR Share of overall employment (as %), 2016 Basel Region
7.6
Øresund
2.4
Switzerland
1.5
Boston
0.9
Singapore
0.9
Munich
0.7
New York
0.5
Paris
0.5
London
0.2 0%
2%
4%
6%
8%
EMPLOYMENT IN THE LIFE SCIENCES SUB-SECTORS Share relative to total employees (as %), 2016 Switzerland
59
34
Basel Region
86 0%
20%
40%
7 6
60%
80%
8 100%
Pharmaceutical industry Medical technology Biotechnology Possible rounding differences
12
PHARMACEUTICAL HUB SWITZERL AND
Source: BAK Economics, 2018
SF Bay Area
Source: BAK Economics, 2018
1.3
Major employers in the pharmaceutical industry Over 33,000 people were employed in the life sciences industry in the Basel Region in 2016. Employment in the life sciences sector accounts for 7.6 per cent of the overall employment. This is above average compared to selected life sciences locations around the world. Considering the life sciences sub-sectors, the pharmaceutical industry clearly dominates the Basel Region: Of all life sciences personnel in the Basel Region cluster, around 28,500 work in the pharmaceutical industry, i.e. about 86 per cent. These figures highlight the major importance of the pharmaceutical industry for the Basel Region.
“The Basel region is Switzerland’s leading life sciences region. More than 400 life sciences companies are located here. Research, development and production are carried out in this region. The Basel Chamber of Commerce is committed to ensuring that good framework conditions prevail so that the life sciences industry in the Basel Region not only maintains its above-average ability to perform and innovate, but can also expand further.” Martin Dätwyler, Director ad interim of the Basel Chamber of Commerce, Head of location policy
BASEL REGION
13
BASEL REGION
VALUE ADDED IN THE LIFE SCIENCES SECTOR Value added relative to regional total value added (as %), 2016 Basel Region
31.4
Øresund
8.9
Switzerland
5.6
Singapore SF Bay Area
2.1
Boston
2.0
New York
1.1
Munich
1.0
Paris
0.9
London
0.4 0%
5%
10%
15%
20%
25%
30%
35%
High value added contribution of life sciences In 2016, the life sciences value added share of the entire cluster value added amounted to approximately 31.4 per cent – by far the highest value in comparative terms. In absolute terms, the life sciences industry in the Basel Region cluster generated around 22.2 billion Swiss francs in 2016, with the pharmaceutical industry alone generating approximately 20.5 billion Swiss francs.
14
PHARMACEUTICAL HUB SWITZERL AND
Source: BAK Economics, 2018
3.9
GROWTH RATE OF REAL GROSS VALUE ADDED AND EMPLOYMENT Average annual growth rate in life sciences (as %), 2006–2016 Singapore Øresund Basel Region Switzerland Munich Boston SF Bay Area New York London –8% –6% –4% –2%
0%
2%
4%
6%
8% 10% 12%
Source: BAK Economics, 2018
Paris
Real gross value added Employment
Positive value added and employment growth Between 2006 and 2016, the real gross value added of the life sciences industry in the Basel Region cluster witnessed an average annual growth rate of around 7 per cent. Employment also increased over the same period with an annual average growth rate of 3.1 per cent. Compared to international life sciences locations, an above- average level of growth has been recorded in the Basel Region life sciences sector.
BASEL REGION
15
BASEL REGION
PRODUCTIVITY IN THE LIFE SCIENCES SECTOR Nominal labour and hourly productivity (in CHF, current prices and exchange rates), 2016 0
175 000
350 000
525 000
700 000
0
175
350
525
700
Basel Region Switzerland SF Bay Area Øresund Singapore London Boston Paris Munich
Nominal labour productivity (top axis) Nominal hourly productivity (below axis)
Highest productivity in the pharmaceutical sector The Basel Region has come out on top compared to other life sciences locations. Thus, in 2016, the life sciences industry in this area generated 474 Swiss francs per working hour or around 667,000 Swiss francs per workplace. Hubs such as Øresund or San Francisco Bay Area are less productive.
16
PHARMACEUTICAL HUB SWITZERL AND
Source: BAK Economics, 2018
New York
“The Basel Region is the Swiss pharmaceutical cluster par excellence, but the whole of Switzerland benefits from the pharmaceutical industry. Accounting for 39% of Switzerland’s exported goods overall, the pharmaceutical industry is the biggest export sector and is therefore central to the Swiss economy.” Elisabeth Schneider-Schneiter, National Councillor and President of the Basel Chamber of Commerce
The pharmaceutical industry is by far the most productive industry and generates a higher value added than other life sciences sub-sectors but with the same number of employees. In 2016, the pharmaceutical industry in the Basel Region cluster generated 511 Swiss francs per working hour or around 719,000 Swiss francs per workplace.
BASEL REGION
17
INNOVATION CAPACITY
18
PHARMACEUTICAL HUB SWITZERL AND
Companies must be able to make dynamic adjustments in order to survive in an ever-changing commercial climate. Innovation – the commercial implementation of new ideas and their impact on the business market – is one of the most important growth factors of a modern economy. For several years, Switzerland has been one of the world’s most innovative countries. Thanks to cutting-edge innovation, Switzerland is a strong competitor in the international stakes. Particularly in knowledge-intensive sectors, capacity for innovation is an important factor when facing location decisions. Companies in the life sciences sector are therefore also interested in locations with a high innovation potential. The framework conditions in the Basel Region cluster that influence the region’s capacity for innovation are shown on the following pages. Research and development expenditure, patent density, the quality of regional universities and the level of education of the workforce are analysed for this purpose.
BASEL REGION
19
INNOVATION CAPACITY
RESEARCH AND DEVELOPMENT EXPENDITURE Share of GDP (as %), 2012 0.3
2.4
Denmark
2.0
0.1
1.0
Switzerland
2.1
0.0
0.8
Germany
2.0
France
1.8
UK
1.0
Spain Italy 0%
0.5
0.4 0.3 0.5
1.5
USA
0.7
0.2
0.2
0.1 0.4
0.7
0.2 0.4
0.7
0.2 0.4 1%
2%
3%
4%
Private sector Public sector Universities
Private sector invests heavily in research and development Intensive research and development will generate new knowledge which, in turn, leads to innovation. A great deal is invested into the research and development of new medicines in Switzerland. Consequently, the pharmaceutical industry contributes to Switzerland’s competitive edge and economic growth. In 2012, research and development expenditure in the private and public sectors coupled with universities accounted overall for approximately 2.9 per cent of the Swiss GDP. Switzerland therefore stands out from the crowd thanks to its intensive research activities and has consolidated its position on the international stage. Investments in R&D are mostly in the private sector: The share of private-sector-financed R&D expenditure accounted for approximately 2 per cent of the GDP in 2012. 20
PHARMACEUTICAL HUB SWITZERL AND
Source: OECD, BAK Economics, 2017
Finland
PATENT APPLICATIONS Number of patent applications per million inhabitants, 2013 Boston
110
Basel Region1
112 46
Øresund
32
Switzerland
24
Munich
92 52 33
80 50
39 50
12 10 24 13
New York
17 15 7
Paris
12 11 10
Singapore
7 11 11
London
7 8 4 0
100
200
300
Pharmaceutical industry Medical technology Biotechnology
Peak values in pharmaceutical patent applications The number of patent applications provides an insight into the innovative capacity of a region. It allows research productivity to be assessed and the commercial value of knowledge to be measured on a worldwide scale. The high commitment to research in the Basel Region cluster is apparent from the patent applications. In 2013, around 112 pharmaceutical patent applications were filed per million inhabitants. Compared to the other Swiss pharmaceutical clusters, most of the patent applications were filed in the Basel Region cluster. With these peak values in the pharmaceutical sector, the Basel Region even surpasses life sciences hubs such as San Francisco Bay Area or Øresund.
1
Basel Region without districts
BASEL REGION
21
Source: OECD, BAK Economics, 2017
SF Bay Area
85 44
INNOVATION CAPACITY
QUALITY OF THE UNIVERSITIES Index 100 = ø of the benchmark areas (Western Europe and USA between 2010 and 2014), 2016 Boston SF Bay Area
112
Singapore
111
Ă˜resund
107
New York
106
Basel Region
104
Switzerland
103
London
102
Paris
100
Munich
100 0
40
80
120
160
High quality of regional universities High-quality academic research institutes attract specialists and high-level scientists from all over the world, thus benefitting other areas in addition to research. The quality of local universities is therefore an important location factor, which is particularly relevant for research-intense sectors such as the pharmaceutical industry. Swiss universities are generally considered as internationally renowned. With 104 points, the universities in the Basel Region cluster have a comparatively good score and rank in the middle tier of the life sciences hubs taken into consideration.
22
PHARMACEUTICAL HUB SWITZERL AND
Source: CWTS Leiden Ranking, BAK Economics, 2017
155
QUALITY OF THE UNIVERSITIES IN THE LIFE SCIENCES SECTOR Index 100 = ø of the benchmark areas (Western Europe and USA between 2010 and 2014), 2016 Boston
131
Ă˜resund
109
Basel Region
105
Switzerland
105
Singapore
105
New York
102
London
99
Paris
99
Munich
99 0
35
70
105
140
Universities in the Basel Region cluster also rank relatively high when compared to international life sciences Universities. The region is renowned for first-class university research and is well placed thanks to the University of Basel and other prestigious institutes such as the Friedrich Miescher Institute, for instance.
BAK Quality of Universities Index The BAK Quality of Universities Index is based on the CWTS Ranking of Leiden and assesses the quality of universities in a given area. It is measured by the number of publications generated by a university in the fields of biomedical and health sciences and their citation frequency.
BASEL REGION
23
Source: CWTS Leiden Ranking, BAK Economics, 2017
113
SF Bay Area
INNOVATION CAPACITY
LEVEL OF EDUCATION Share of gainfully employed (as %), 2014 41
Finland
41
Switzerland
38
Spain
37
France
36
Denmark
34
Austria
42
45
19 22
54
15
60
19 0%
15 39
44
27
Italy
13
48 23
32
Germany
17
46
13
47 20%
40%
34 60%
80%
100%
Tertiary Secondary Primary Possible rounding differences
24
PHARMACEUTICAL HUB SWITZERL AND
Source: OECD, BAK Economics, 2017
UK
Highly qualified workforce Employees’ qualifications are an important indicator of the competitive edge and innovative capacity of an economy. For sectors with a high research and development activity, such as the pharmaceutical industry, professionals with tertiary education are particularly important. In 2014, the proportion of tertiary-educated employees in Switzerland accounted for more than one third (38%) of all those in gainful employment, compared to just under one quarter in 2000. Employees with secondary education still represent the largest share with approximately 48 per cent. Compared to other European countries, Switzerland has a high level of education.
BASEL REGION
25
INWARD INVESTMENT FACTORS
26
PHARMACEUTICAL HUB SWITZERL AND
In addition to in-house variables, inward investment factors are also important for companies in order to optimise their economic activity. In the light of globalisation, inward investment factors are of increasing commercial importance. The inward investment factor discussion can be viewed from two perspectives: Whereas hard factors such as taxation and regulation are mostly relevant for companies, other factors including the level of education and quality of life are more important for employees. An improvement in regional location quality is therefore important in order to remain attractive for companies already settled or interested in settling in a given area as well as for highly qualified employees. Various indicators from the areas of taxation, accessibility and regulation are considered on the following pages to evaluate the location quality of the Basel Region cluster.
BASEL REGION
27
INWARD INVESTMENT FACTORS
MARKET REGULATION
4.0
IT FR
3.0
FR
IT 2.0 DE 1.0 0.0 0.0
UK 0.5
1.0
FI DK
FI CH
UK
CH US
US 1.5
ES
DK
ES
DE
2.0
2.5
3.0
3.5
PRODUCT MARKET REGULATION INDEX
2015 1995
Economy-friendly regulation State regulations can lead to high administrative costs or preclude market access. However, at the same time, regulations can also promote competition and economy-friendly structures. The intensity of (labour and product) market regulation therefore has a significant impact on the attractiveness of a location. Generally, it should be noted that all comparative countries were regulated to less of an extent in 2015 compared to 1995. The international comparison of the way labour and product markets are regulated shows that Switzerland had a moderate level of regulation in 2015. Whilst the Anglo-Saxon countries in particular have an even more liberal market structure, regulation in Spain, Italy and especially France is essentially higher than in Switzerland.
28
PHARMACEUTICAL HUB SWITZERL AND
Source: OECD, Cato Institute, BAK Economics, 2017
LABOUR MARKET REGULATION INDEX
Product and labour market regulation index (0 = very liberal; 6 = strictly regulated), 1995 and 2015
BAK TAXATION INDEX Taxation of companies and highly qualified workforce, ø 1995–2017 New York Boston Munich
30%
SF Bay Area Paris
London
20%
Øresund
Basel Region 10%
Singapore
0% 0%
10%
20%
30%
40%
50%
60%
TAXATION OF HIGHLY QUALIFIED WORKFORCE
Competitive taxation system Taxation is one of the most important factors in international competition for business locations. This is because the tax system of an area is extremely important for both companies and employees alike. Switzerland and its areas have a competitive tax system. The Basel Region is attractive based on an international comparison of taxation systems. Both corporate taxation and the taxation of highly qualified employees are lower compared to other international life sciences locations.
Measurement of taxation (Taxation Index) Company taxation including all indirect company taxes and/or for a highly qualified employee earning 100,000 euros after tax.
BASEL REGION
29
Source: ZEW, BAK Economics, 2017
TAXATION OF COMPANIES
40%
INWARD INVESTMENT FACTORS
DOING BUSINESS INDEX Maximum: Index 100, 2010 and 2015 Denmark UK Finland Germany Switzerland France Spain Italy 0
15
30
45
60
75
90
2010 2015
Competitive conditions In 2015, Switzerland ranked 26th2 in the Doing Business Index and was therefore in the middle tier of high-earning OECD countries. In terms of a European comparison, Switzerland ranked behind the Nordic countries and in front of the Southern European countries.
Doing Business Index The index ranks economies according to their ease of doing business. The higher the ranking, the more business-friendly the regulatory conditions are in terms of starting and operating a local firm.
2
Source: The World Bank, 2016
30
PHARMACEUTICAL HUB SWITZERL AND
Source: World Bank, BAK Economics, 2017
USA
GLOBAL ACCESSIBILITY London
120
Paris
119
Ă˜resund
112
New York
112
Munich
111
Boston
109
Basel Region
109
Switzerland
109
SF Bay Area
94 0
20
40
60
80
100
120
140
Good connections Accessibility of production locations and markets plays a major role when choosing a business location. As various corporate processes often take place in different locations in the course of globalisation, international networking is particularly important. In the Global Accessibility Index, the Basel Region with 109 points ranks behind other international life sciences hubs. However, it has good international connections thanks to its proximity to France and Germany, and enjoys excellent access to an important freight traffic route with the Swiss Rhine ports.
Measurement of accessibility (Accessibility Index) Indexed value that quantifies the global accessibility of a region. It reflects the outbound accessibility from a region to locations in the rest of the world. BASEL REGION
31
Source: TransSol, BAK Economics, 2017
Index (100 = ø of all areas inspected 2002), 2016
COMPANY PROFILES
Actelion Actelion Pharmaceuticals Ltd is part of the Janssen pharmaceutical companies of Johnson & Johnson. Actelion is a pioneer in the field of pulmonary arterial hypertension (PAH). The PAH portfolio covers the disease spectrum of WHO functional classification II to IV and includes medicines for oral, inhalable and intravenous therapy. Janssen has added pulmonary hypertension as the sixth therapeutic focus in order to maintain Actelion’s leading position in this important medical sector. Actelion also has treatments that are approved by the regulatory authorities but not available in all countries for a number of diseases that require specialist treatment. These include Gaucher’s disease type 1, Niemann-Pick disease type C, digital ulcerations in patients with systemic sclerosis and also cutaneous T cell lymphoma of the mycosis fungoides type. www.actelion.com
32
PHARMACEUTICAL HUB SWITZERL AND
Bayer Location Basel Bayer is a life sciences company with over 150 years of history and core competencies in health and agricultural economics. We develop new molecules to improve human, animal and plant health with innovative products and solutions. The growing and increasingly ageing world population calls for constant improvements in medical care and adequate nutrition. Bayer improves quality of life by preventing, alleviating and curing diseases. And we help to ensure an adequate supply of high-quality food and animal feed and renewable plant-based raw materials. Bayer employs more than 1,000 people in Switzerland today at its headquarters in Zurich and at other sites. The Consumer Health Division – a global pharmaceutical and cross-sector entity – is based in Basel with a workforce of 750 people from over 60 nations. www.bayer.ch
BASEL REGION
33
COMPANY PROFILES
Boehringer Ingelheim Boehringer Ingelheim is a group that maintains global operations with 143 group companies in 50 countries and employs over 45,600 people. Boehringer Ingelheim emÂÂ ploys around 100 people in Switzerland and is active in the fields of human pharmaceuticals and animal health. The family-owned company, which was created in 1885, has the following key areas, namely cardiometabolic diseases, diabetes and respiratory tract diseases, cancer, central nervous system disorders and immunology. www.boehringer-ingelheim.ch
34
PHARMACEUTICAL HUB SWITZERL AND
Novartis Novartis is the largest healthcare company in Switzerland and one of the biggest exporters. The company offers a diversified portfolio in order to meet the changing needs of patients and societies as well as possible with innovative medicines, products for eye care and low-cost generic medicines. Novartis is the only company with world-leading positions in all these fields. The company was formed in 1996 by the merger of Ciba-Geigy and Sandoz. Novartis operates in more than 140 countries but is rooted in Switzerland. The company employs around 123,000 people worldwide. Of these, around 13,000 work in Switzerland – spread over a total of eight sites: Basel (BS), Schweizer halle (BL), Fribourg (FR), Geneva (GE), Locarno (TI), Rotkreuz (ZG), Schaffhausen (SH) and Stein (AG). www.novartis.ch
BASEL REGION
35
COMPANY PROFILES
Roche Roche is one of the world’s leading research-based healthcare companies with two strong core businesses: pharmaceuticals and diagnostics. The Roche Group, with headquarters in Basel, operates in over 100 countries and had over 94,000 employees worldwide in 2016. Roche is the world’s biggest Biotech company supplying differentiated medicines for oncology, immunology, infectious diseases, ophthalmology and central nervous system disorders. Basel/Kaiseraugst is one of the largest sites worldwide with around 11,400 employees from more than 90 nations. Not only is the corporate management located here but also all of the global functions. Roche Pharma (Schweiz) AG in Reinach is responsible for sales & marketing and medical affairs as well as the registration and quality assurance of Roche medicines in Switzerland. Approximately 150 employees from over eight nations are employed in Reinach. www.roche.ch
36
PHARMACEUTICAL HUB SWITZERL AND
GLOSSARY
FSO GDP GVA ISIC OECD R&D
Federal Statistical Office, Switzerland Gross Domestic Product Gross Value Added International Standard Industrial Classification of All Economic Activities Organisation for Economic Co-operation and Development Research and Development
Information on areas Boston Boston-Cambridge-Newton Munich Munich Region New York New York-Newark-Jersey City SF Bay Area San Francisco Bay Area Demarcation of the life sciences industry The definition of the life sciences industry used in this publication includes the following ISIC branches: Pharmaceutical Industry (21), Electronic Medical Technology (26.6), Orthopaedic Medical Technology (32.5) and Research and Development on Biotechnology (72.11).
38
PHARMACEUTICAL HUB SWITZERL AND
Publishing information Published by: Interpharma Association of research-based pharmaceutical companies in Switzerland Petersgraben 35 P.O. Box 4009 Basel Phone: 061 264 34 00 E-mail: info@interpharma.ch Website: www.interpharma.ch
The content of the publication can also be found on the Interpharma website at www.interpharma.ch. Graphics from the latest version may be downloaded for your free use provided the source is quoted. Design: Continue AG, Basel Print: Gremper AG, Pratteln Deutsche Originalversion verfßgbar Š Interpharma, 2018 Photocopying permitted with acknowledgement of source
Interpharma Petersgraben 35, P.O. Box CH-4009 Basel Phone +41 (0)61 264 34 00 Fax +41 (0)61 264 34 01 info@interpharma.ch www.interpharma.ch